{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:26:05Z","timestamp":1787019965061,"version":"build-2736575974"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82405217"],"award-info":[{"award-number":["82405217"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82474260"],"award-info":[{"award-number":["82474260"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Shanghai Science Technology and Innovation Action Plan","award":["24YF2741500"],"award-info":[{"award-number":["24YF2741500"]}]},{"name":"hanghai Science Technology and Innovation Action Plan","award":["21Y31920400"],"award-info":[{"award-number":["21Y31920400"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biol Proced Online"],"DOI":"10.1186\/s12575-025-00311-3","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T14:15:02Z","timestamp":1765289702000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Arsenic Sulfide Induces Apoptosis in Myelodysplastic Neoplasm Cells Through the Suppression of ABI2"],"prefix":"10.1186","volume":"27","author":[{"given":"Yuchen","family":"Tao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runfeng","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyang","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yirong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianye","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Ba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahui","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,9]]},"reference":[{"key":"311_CR1","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1056\/NEJMra1904794","volume":"383","author":"M Cazzola","year":"2020","unstructured":"Cazzola M. Myelodysplastic syndromes. N Engl J Med. 2020;383:1358\u201374.","journal-title":"N Engl J Med"},{"key":"311_CR2","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1182\/blood.2023020078","volume":"142","author":"RP Hasserjian","year":"2023","unstructured":"Hasserjian RP, Germing U, Malcovati L. Diagnosis and classification of myelodysplastic syndromes. Blood. 2023;142:2247\u201357.","journal-title":"Blood"},{"key":"311_CR3","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022;36:1703\u201319.","journal-title":"Leukemia"},{"key":"311_CR4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00428-022-03417-1","volume":"482","author":"RP Hasserjian","year":"2023","unstructured":"Hasserjian RP, Orazi A, Orfao A, Rozman M, Wang SA. The international consensus classification of myelodysplastic syndromes and related entities. Virchows Arch. 2023;482:39\u201351.","journal-title":"Virchows Arch"},{"key":"311_CR5","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1080\/14737140.2024.2414071","volume":"24","author":"A Bidikian","year":"2024","unstructured":"Bidikian A, Bewersdorf JP, Shallis RM, Getz TM, Stempel JM, Kewan T, et al. Targeted therapies for myelodysplastic syndromes\/neoplasms (MDS): current landscape and future directions. Expert Rev Anticancer Ther. 2024;24:1131\u201346.","journal-title":"Expert Rev Anticancer Ther"},{"key":"311_CR6","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1182\/blood-2016-10-696062","volume":"129","author":"A Shastri","year":"2017","unstructured":"Shastri A, Will B, Steidl U, Verma A. Stem and progenitor cell alterations in myelodysplastic syndromes. Blood. 2017;129:1586\u201394.","journal-title":"Blood"},{"key":"311_CR7","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1126\/science.1173041","volume":"324","author":"S-Y Park","year":"2009","unstructured":"Park S-Y, Fung P, Nishimura N, Jensen DR, Fujii H, Zhao Y, et al. Abscisic acid inhibits type 2 C protein phosphatases via the PYR\/PYL family of START proteins. Science. 2009;324:1068\u201371.","journal-title":"Science"},{"key":"311_CR8","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/S1369-5266(98)80265-3","volume":"1","author":"E Grill","year":"1998","unstructured":"Grill E, Himmelbach A. ABA signal transduction. Curr Opin Plant Biol. 1998;1:412\u20138.","journal-title":"Curr Opin Plant Biol"},{"key":"311_CR9","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1111\/liv.15412","volume":"42","author":"J Chen","year":"2022","unstructured":"Chen J, Li H, Zhang B, Xiong Z, Jin Z, Chen J, et al. Abi2-mediated MEOX2\/KLF4-NANOG axis promotes liver cancer stem cell and drives tumour recurrence. Liver Int. 2022;42:2562\u201376.","journal-title":"Liver Int"},{"key":"311_CR10","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1124\/jpet.122.001255","volume":"384","author":"I Hofmann","year":"2023","unstructured":"Hofmann I, Baum A, Hofmann MH, Trapani F, Reichel-Voda C, Ehrensperger D, et al. Pharmacodynamic and antitumor activity of BI 836880, a dual vascular endothelial growth factor and angiopoietin 2 inhibitor, alone and combined with programmed cell death protein-1 inhibition. J Pharmacol Exp Ther. 2023;384:331\u201342.","journal-title":"J Pharmacol Exp Ther"},{"issue":"28","key":"311_CR11","first-page":"5073","volume":"39","author":"Y Li","year":"2020","unstructured":"Li Y, Wang H, Zhang L, et al. BAI1 acts as a tumor suppressor in lung cancer A549 cells by inducing metabolic reprogramming via the SCD1\/HMGCR module. Oncogene. 2020;39(28):5073\u201386.","journal-title":"Oncogene"},{"key":"311_CR12","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.peptides.2012.09.007","volume":"38","author":"JB Wang","year":"2012","unstructured":"Wang JB, Wang MD, Li EX, Dong DF. Advances and prospects of anginex as a promising anti-angiogenesis and anti-tumor agent. Peptides. 2012;38:457\u201362.","journal-title":"Peptides"},{"key":"311_CR13","doi-asserted-by":"publisher","DOI":"10.4414\/smw.2019.14697","volume":"149","author":"O Boyman","year":"2019","unstructured":"Boyman O, Arenas-Ramirez N. Development of a novel class of interleukin-2 immunotherapies for metastatic cancer. Swiss Med Wkly. 2019;149:w14697.","journal-title":"Swiss Med Wkly"},{"key":"311_CR14","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.cbpa.2012.01.015","volume":"16","author":"J-X Liu","year":"2012","unstructured":"Liu J-X, Zhou G-B, Chen S-J, Chen Z. Arsenic compounds: revived ancient remedies in the fight against human malignancies. Curr Opin Chem Biol. 2012;16:92\u20138.","journal-title":"Curr Opin Chem Biol"},{"key":"311_CR15","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1182\/blood.2019000760","volume":"134","author":"H-H Zhu","year":"2019","unstructured":"Zhu H-H, Hu J, Lo-Coco F, Jin J. The simpler, the better: oral arsenic for acute promyelocytic leukemia. Blood. 2019;134:597\u2013605.","journal-title":"Blood"},{"key":"311_CR16","doi-asserted-by":"publisher","first-page":"6425","DOI":"10.1182\/blood-2010-11-283598","volume":"117","author":"S-J Chen","year":"2011","unstructured":"Chen S-J, Zhou G-B, Zhang X-W, Mao J-H, de Th\u00e9 H, Chen Z. From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia. Blood. 2011;117:6425\u201337.","journal-title":"Blood"},{"key":"311_CR17","doi-asserted-by":"publisher","first-page":"4826","DOI":"10.1073\/pnas.0712365105","volume":"105","author":"L Wang","year":"2008","unstructured":"Wang L, Zhou G-B, Liu P, Song J-H, Liang Y, Yan X-J, et al. Dissection of mechanisms of Chinese medicinal formula realgar-indigo naturalis as an effective treatment for promyelocytic leukemia. Proc Natl Acad Sci U S A. 2008;105:4826\u201331.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"311_CR18","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1080\/08923973.2024.2344158","volume":"46","author":"Y Tao","year":"2024","unstructured":"Tao Y, Xue T, Li X, Guo R, Wang Y, Xu H, et al. Comparative analysis of immunological changes following Realgar and arsenic trioxide treatments in a murine model of myelodysplastic syndrome. Immunopharmacol Immunotoxicol. 2024;46:408\u201316.","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"311_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-025-03768-0","volume":"25","author":"H Xu","year":"2025","unstructured":"Xu H, Hu K, Wang Y, Cai S, Wu F, Bao J, et al. Single-cell transcriptome sequencing reveals the mechanism of Realgar improvement on erythropoiesis in mice with myelodysplastic syndrome. Cancer Cell Int. 2025;25:135.","journal-title":"Cancer Cell Int"},{"key":"311_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2025.119339","volume":"341","author":"T Xue","year":"2025","unstructured":"Xue T, Tao Y, Wu Z, Yuan C, Wang Y, Xu H, et al. Realgar induces apoptosis by inhibiting glycolysis via regulating STAT3 in myelodysplastic syndrome. J Ethnopharmacol. 2025;341:119339.","journal-title":"J Ethnopharmacol"},{"key":"311_CR21","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.leukres.2017.09.010","volume":"62","author":"M Xu","year":"2017","unstructured":"Xu M, Ren J-Y, Guo Y-C, Xu B-X, Zeng Q, Hu Q, et al. Effects of arsenic disulfide on apoptosis, histone acetylation, toll like receptor 2 activation, and erythropoiesis in bone marrow mononuclear cells of myelodysplastic syndromes patients in vitro. Leuk Res. 2017;62:4\u201311.","journal-title":"Leuk Res"},{"key":"311_CR22","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1089\/scd.2009.0113","volume":"18","author":"V Kashyap","year":"2009","unstructured":"Kashyap V, Rezende NC, Scotland KB, Shaffer SM, Persson JL, Gudas LJ, et al. Regulation of stem cell pluripotency and differentiation involves a mutual regulatory circuit of the NANOG, OCT4, and SOX2 pluripotency transcription factors with polycomb repressive complexes and stem cell microRNAs. Stem Cells Dev. 2009;18:1093\u2013108.","journal-title":"Stem Cells Dev"},{"issue":"7","key":"311_CR23","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1002\/stem.1384","volume":"31","author":"A Saunders","year":"2013","unstructured":"Saunders A, Faiola F, Wang J. Concise review: pursuing self-renewal and pluripotency with the stem cell factor Nanog. Stem Cells. 2013;31(7):1227\u201336.","journal-title":"Stem Cells"},{"key":"311_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12918-018-0552-3","volume":"12","author":"P Yu","year":"2018","unstructured":"Yu P, Nie Q, Tang C, Zhang L. Nanog induced intermediate state in regulating stem cell differentiation and reprogramming. BMC Syst Biol. 2018;12:22.","journal-title":"BMC Syst Biol"},{"issue":"8","key":"311_CR25","first-page":"1745","volume":"7","author":"J Chen","year":"2023","unstructured":"Chen J, Liu X, Zhao Y, et al. Targeting HDAC3 to overcome the resistance to ATRA or arsenic in acute promyelocytic leukemia through ubiquitination and degradation of PML-RAR\u03b1. Blood Adv. 2023;7(8):1745\u201358.","journal-title":"Blood Adv"},{"key":"311_CR26","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/978-3-031-62731-6_14","volume":"1459","author":"U Testa","year":"2024","unstructured":"Testa U, Pelosi E. Function of PML-RARA in acute promyelocytic leukemia. Adv Exp Med Biol. 2024;1459:321\u201339.","journal-title":"Adv Exp Med Biol"},{"key":"311_CR27","first-page":"99","volume":"809","author":"HR Chang","year":"2018","unstructured":"Chang HR, Munkhjargal A, Kim M-J, Park SY, Jung E, Ryu J-H, et al. The functional roles of PML nuclear bodies in genome maintenance. Mutat Res. 2018;809:99\u2013107.","journal-title":"Mutat Res"}],"container-title":["Biological Procedures Online"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12575-025-00311-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12575-025-00311-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12575-025-00311-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T14:15:03Z","timestamp":1765289703000},"score":1,"resource":{"primary":{"URL":"https:\/\/biologicalproceduresonline.biomedcentral.com\/articles\/10.1186\/s12575-025-00311-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["311"],"URL":"https:\/\/doi.org\/10.1186\/s12575-025-00311-3","relation":{},"ISSN":["1480-9222"],"issn-type":[{"value":"1480-9222","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,9]]},"assertion":[{"value":"17 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"47"}}